June, 2023, Guangzhou JOYO Pharma Co., Ltd (JOYO PHARMA)announced that it has completed the pre-C round of financing of more than 100 million yuan. The investors are Chengdu Biocity Equity Investment Fund, Anxin Guosheng Microchip Pharmaceutical Health Equity Investment Fund, and Triwise Capital.JOYO Pharma is an innovative drug developing company, driven by translational medicine and clinical medicine, focusing on area of tumors, autoimmunity, metabolism and infectious diseases. This round of financing will be used for the promotion of multiple mid-to-late stage clinical projects of the company’s innovative drug pipeline, especially the clinical phase III of innovative drugs targeting global major public health problems and infectious diseases, as well as Phase II clinical trials in multiple disease areas such as tumors and autoimmunity.
JOYO PHARMA is a biopharmaceutical company specializing in the research and development of innovative drugs. It has research and development bases in Zhangjiang, Shanghai, Guangzhou Development Zone, and Hangzhou Binjiang Development Zone.
Among them, the Class 1 innovative drug Sertapyridine (WX-081) Tablets has recently launched a multi-center, randomized, double-blind, positive drug-controlled phase 3 clinical study at the National Investigators Meeting for the treatment of rifampicin-resistant pulmonary tuberculosis patient. Serdapyridine (WX-081) is a new anti-tuberculosis drug candidate optimized on the basis of the structure of Betaquinoline. Studies based on in vitro and in vivo tests in animal models have shown that WX-081 has comparable efficacy against tuberculosis compared with Betaquinoline, but has lower cardiotoxicity and more favorable pharmacokinetic properties.[1]Zhu R, Shang Y, Chen S, etc. In Vitro Activity of the Sudapyridine (WX-081) against Non-tuberculous Mycobacteria Isolated in Beijing, China, Microbiol Spectr, 2022 Oct 17: e0137222. doi: … Continue reading
JOYO PHARMA follows the philosophy of “In China, for Global” and focuses on tumors, autoimmunity, metabolism and infectious diseases. JOYO PHARMA has a number of innovative drug projects, and a number of clinical trials are being promoted simultaneously at present.[2]Guangzhou Joyo Pharma Co Ltd, Wechat official account
References
